A New Zealand biotech company hopes results from a clinical trial it plans to run in Auckland could ultimately reduce the need for MIQ and limit vaccine wastage around the world.
Auckland-based Pictor Limited is seeking 300 volunteers for a trial of its COVID-19 IgG antibody test, which can determine whether someone has a Covid spike protein, indicating they’ve been vaccinated, or whether they have both the spike and nucleocapsid proteins, indicating they’ve previously had Covid and are now free of the infection. The company says the test could be used to identify people at the border who are less of a risk and might not need 14 days isolation.
Kathryn is joined by Pictor’s US-based consulting chief medical officer Tadd Lazarus.
|Media Contact – NZ/Australia |
Mark Russell Mark@hotmetal.nz
+64 21 297 0178